ghdx has a great product and is increasing sales every 1/4, so far. the company is relatively new and is still not profitable.
i was hoping that last 1/4 they would have broken even. now they have launched another product that seems to have good prospects. time will tell but moving into the black is a must before any expected stock price appreciation can be expected.
Currently, we're down at the lower end. Stock is probably still weak from the pre-announced rev shortfall from the delayed insurance compnay payments. Longer term, probably still a little disappointment with the colon test not meeting the endpoint for predictive benefit. Analysts seem to want to see something else in the pipeline to follow the breast test (which is gang busters)....and prognostic for colon (30,000 US cases per year) didn't seem to excite them.
This company will continue to steadily expand....grow revs, eps, etc....but next big move might be dependent on product line extension....and the market isn't expecting any shockers from GHI at ASCO...so it underperforms for now....just my guesses...